Treatment of Anxiety in Parkinson's Disease Patients on Levodopa/Carbidopa and Lamotrigine
For anxiety in a Parkinson's patient already on levodopa/carbidopa and lamotrigine, start with an SSRI (escitalopram, sertraline, or paroxetine) as first-line pharmacotherapy, while optimizing levodopa dosing to minimize "off" periods that exacerbate anxiety.
Rationale and Treatment Algorithm
Step 1: Optimize Dopaminergic Therapy First
Before adding anxiolytic medication, assess whether anxiety correlates with motor fluctuations. Anxiety in Parkinson's disease is strongly linked to "off" periods and improves with levodopa optimization 1, 2. A dose-response study demonstrated that levodopa produces robust, dose-dependent reductions in anxiety (not placebo effects), with higher infusion rates producing more rapid onset and greater magnitude of anxiety relief 2.
- Evaluate timing of anxiety symptoms relative to levodopa dosing
- If anxiety worsens during "off" periods, adjust levodopa/carbidopa dosing intervals or total daily dose before adding anxiolytics
- Consider that levodopa itself has direct anxiolytic properties through dopaminergic mechanisms 2
Step 2: Initiate SSRI Therapy
SSRIs are the recommended first-line pharmacological treatment for anxiety in Parkinson's disease 3, 1, 4. While no RCTs have specifically targeted anxiety as a primary outcome in PD, meta-analysis of depression trials (where anxiety was a secondary outcome) showed moderate anxiolytic effects (standardized mean difference: -0.45, p = 0.02) 3.
Preferred SSRIs:
- Escitalopram (first choice - best tolerability profile)
- Sertraline (alternative)
- Paroxetine (effective but more anticholinergic side effects)
Start at low doses and titrate slowly due to potential drug interactions with levodopa/carbidopa 5.
Step 3: Monitor for Drug Interactions
Critical caveat: The levodopa/carbidopa FDA label warns that tricyclic antidepressants can cause adverse reactions including hypertension and dyskinesia when combined with carbidopa-levodopa preparations 5. While SSRIs are safer, monitor for:
- Worsening dyskinesias
- Orthostatic hypotension (especially if adding other medications)
- Serotonin syndrome (theoretical risk with dopaminergic agents)
Lamotrigine consideration: The patient is already on lamotrigine, which has been studied for pain management in PD 6 but has no specific anxiolytic indication. It does not contraindicate SSRI use.
Step 4: Avoid Benzodiazepines
Do not use benzodiazepines as first-line treatment despite their anxiolytic properties. Only one study (bromazepam) showed efficacy for anxiety in PD 4, but benzodiazepines significantly increase fall risk and confusion in this population 1, 4. The risk-benefit ratio is unfavorable given safer alternatives.
Step 5: Consider Non-Pharmacological Interventions
Cognitive behavioral therapy (CBT) should be offered alongside pharmacotherapy when feasible 4. A multimodal approach combining psychotherapy with medication produces better outcomes than either alone, though this requires access to trained therapists.
Evidence Quality and Limitations
Major gap in evidence: No high-quality RCTs have studied anxiety as a primary outcome in PD 3, 1, 7. Current recommendations are based on:
- Secondary outcome data from depression trials
- Uncontrolled studies showing SSRI benefit
- Clinical experience and extrapolation from general anxiety disorder guidelines
The social anxiety disorder guidelines [8-8] are not directly applicable here because they explicitly exclude patients with neurodegenerative diseases and organic brain diseases, making them irrelevant to this Parkinson's patient.
Common Pitfalls to Avoid
Undertreating anxiety: Studies show 57% of PD patients with anxiety disorders receive no treatment, and 83% of those treated still have active symptoms 7. Be aggressive with treatment.
Ignoring motor fluctuations: Failing to recognize that anxiety may be a non-motor manifestation of "off" periods leads to inappropriate polypharmacy when levodopa adjustment would suffice 1, 2.
Using dopamine antagonists: Metoclopramide and antipsychotics (phenothiazines, butyrophenones, risperidone) can worsen PD and reduce levodopa efficacy 5. Avoid these even for nausea or agitation.
Premature dose escalation: Both SSRIs and levodopa adjustments require 4-6 weeks to assess full therapeutic effect. Allow adequate trial periods before declaring treatment failure.
Practical Starting Regimen
- Escitalopram 5 mg daily (increase to 10 mg after 1-2 weeks if tolerated)
- Continue current levodopa/carbidopa and lamotrigine
- Reassess anxiety symptoms and motor fluctuations at 4-6 weeks
- If partial response, increase SSRI to maximum tolerated dose before adding additional agents
- Document "off" time and anxiety correlation using patient diaries
The evidence strongly supports SSRIs as first-line treatment while optimizing dopaminergic therapy, despite the limited quality of available studies 3, 1, 4.